January 11, 2018: TECHFIELDS HAS BEGUN PHASE 3 CLINICAL TRIALS OF X0002

Techfields has begun a Phase III clinical trial of a novel drug-X0002, TF-X0002-32(Bettermove-2), in 76 sites in the US for the treatment of the Lumbar Spine. The study title is:

A Phase 3, Multicenter, 22-Week, Double-blind and 30-Week Open Label Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of X0002 Spray in Relief of Pain of Subjects with Osteoarthritis of the Lumbar Spine.